Acute Lymphoblastic Leukemia (ALL)
Clolar is indicated for the treatment of patients 1 to 21 years old with acute lymphoblastic leukemia (ALL) who have had at least 2 treatment regimens and whose ALL has recurred or resisted treatment.
This indication is based upon the percentage of patients whose ALL responded to Clolar treatment. There are no trials showing whether or not disease-related symptoms or survival improved with Clolar.
For more information, please consult the full Prescribing Information.
Patient Assistance with Sanofi Patient Connection
For more information about Sanofi Patient Connection, call to speak with one of our counselors:
- Monday - Friday, 9:00 a.m. – 8:00 p.m. Eastern Time
or click here to visit our site
Multi-lingual assistance is available.
Clolar prescribing information